PT-141 Dosage Chart: The Vyleesi Label Dose and Male-Trial Data
PT-141 dosage chart: units per dose by vial size, the Vyleesi FDA label dose (1.75 mg SC), the trial behind it, and the older 10 mg intranasal male study.
The short version
The only PT-141 (bremelanotide) dose established by regulators is the Vyleesi label dose: 1.75 mg by subcutaneous injection, at least 45 minutes before sexual activity. It can be used no more than once in 24 hours and no more than eight times a month. That figure comes from a dose-ranging trial in premenopausal women. A separate, older trial in men used a different route and a much larger amount, 10 mg intranasal. That is not the approved regimen and never became one.
- The only approved dose is 1.75 mg subcutaneous, as needed, capped at once per day and eight times monthly.
- That dose was chosen in a Phase 2b trial that tested it against other doses in the same population.
- The main male trial used 10 mg intranasal. That is a different route and dose from the approved one, so no grey-market seller can cite it for the injectable product.
- The dosage chart on this page shows units per dose by vial size. The actual strength of a research-labelled vial is still unverified.
PT-141 dosage chart
The FDA-approved PT-141 product is dosed as its label directs and a prescriber sets the dose. For vials that need mixing, this is each label dose in units on a U-100 insulin syringe, by vial size.
10 mg vialwith 1 mL water
| Dose | Units | Volume | Doses per vial |
|---|---|---|---|
| 1.75 mg | 17.5 units | 0.175 mL | 5 |
Full 10 mg vial page: other water volumes, mixing, storage →
U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. Arithmetic only. Other numbers: peptide calculator.
This page covers dose, frequency and limits only. For what the evidence shows and who it was tested on, see the main PT-141 guide.
PT-141 dosage: the approved dose
US legal status - FDA-approved · prescription only
Vyleesi (bremelanotide) is FDA-approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder, at a labelled dose of 1.75 mg subcutaneously as needed.
The label states a single dose, with hard limits on how often it can be repeated:
| Element | Label instruction |
|---|---|
| Dose | 1.75 mg |
| Route | Subcutaneous injection, abdomen or thigh |
| Timing | At least 45 minutes before anticipated sexual activity |
| Frequency cap | No more than one dose in 24 hours |
| Monthly cap | No more than eight doses in a month |
The dose is a single fixed amount, used as needed within those limits, for the approved population. There is no titration and no daily schedule.
Where the 1.75 mg figure came from
A Phase 2b dose-ranging study tested bremelanotide across a range of subcutaneous doses. The women had hypoactive sexual desire disorder, alone or combined with female sexual arousal disorder. The 1.75 mg dose was carried forward because it reached statistical significance against placebo across every efficacy endpoint the study measured Althof 2019 - Althof S, Derogatis LR, Greenberg S et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235., in the references below.
That same dose was then used, unchanged, in the two Phase 3 RECONNECT trials that support the approval. They ran for 24 weeks of at-home, as-needed use Kingsberg 2019 - Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908., in the references below.
PT-141 doses used in the male study
What is not established
- No approved dose exists for men. The approval, the label, and both Phase 3 trials are in premenopausal women. The main male data uses a different route and dose, from a 2008 trial that did not lead anywhere regulatory.
- No dose is established for an unverified research-chemical vial. Even where a vial is sold under the same name, no one has verified its concentration. The label’s 1.75 mg cannot be safely assumed to be what a given vial delivers per injection.
- No cycling or loading protocol is supported by the label or the trials. As needed, within the stated caps, is the entire approved regimen.
Reconstitution arithmetic
Vyleesi is dispensed as a ready-to-use single-dose autoinjector. The patient does not reconstitute it. If you are working out draw volume or concentration for a vial of any kind, that arithmetic is not health advice and is not covered here. Use the dosage calculator.
PT-141 side effects and risks
The label describes transient increases in blood pressure and decreases in heart rate after injection, typically resolving within about 12 hours. It advises against use in anyone with uncontrolled high blood pressure or known cardiovascular disease.
Focal skin hyperpigmentation has been reported, more often in people with darker skin. The label notes that resolution after stopping was not confirmed in every patient. Nausea was the most commonly reported reaction in trials, affecting roughly 40% of participants on the drug.
Unit conversion for a PT-141 vial: PT-141 dosage calculator.
Where to get PT-141 legally
PT-141 is an FDA-approved prescription medicine, so the legal route is a licensed prescriber, in person or by telehealth, and a licensed pharmacy.
With a prescription, Vyleesi costs $99 for a 4-dose box without insurance, says its maker, Cosette Pharmaceuticals (as of 3 October 2026).
Every legal route for PT-141, with dated prices →
How telehealth prescribing works, what it costs and what to check: telehealth peptide prescribing.
Research-labelled PT-141 (not the approved medicine)
These checked vendors sell a research-labelled version. It has not been reviewed by FDA, is labelled not for human use, and is tested only as the seller chooses.
1.Next Level Pharm
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
2.Spartan Peptides
10 mg vial
- No FDA warning letter found
- Names its testing lab
3.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
How research-labelled PT-141 differs, and what FDA has said →
Common questions
What is the approved dose of PT-141?
1.75 mg, injected subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. The label caps it at one dose in any 24-hour period and no more than eight doses in a month.
Is PT-141 taken daily?
No. The approved regimen is as needed before activity, not a daily injection and not a cycle. Many vendor protocols for unapproved PT-141 describe it differently.
Why do some sources mention a 10 mg dose?
That figure comes from an older randomised trial in men who had not responded to sildenafil. It tested bremelanotide as a 10 mg intranasal spray, a different route and an amount about 5.7 times larger than the approved subcutaneous dose. It did not lead to an approval and is not the regimen used today.
Can I use the approved dose for a research-chemical vial?
No. An unverified vial has no confirmed concentration, so a label dose cannot be safely mapped onto it without knowing exactly what is in the vial and at what strength. This page does not solve that arithmetic and quality problem. The dosage calculator link below covers the maths, and the compound page explains why an unverified vial is a downgrade from the approved product.
References (5 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.Randomised trialPMID 31599840full text
- 2.Althof S, Derogatis LR, Greenberg S et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235.Randomised trialPMID 31277966
- 3.Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.Randomised trialPMID 18206919
- 4.Safarinejad MR, Hosseini SY. Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. 2023.StudyPMID 36626345
- 5.VYLEESI (bremelanotide) injection - full prescribing information: dosage, administration limits and warnings.- DailyMed, National Library of Medicinelabel